Monday, July 21, 1997
One lesson that could be drawn from years of experience with very early
stage research is that such work should be incubated in a non-corporate setting for as
long as possible. Nevertheless, the lure of owning a piece of a biotech company remains
strong, as evidenced by the announcement last week of a new virtual company, Helicon Therapeutics Inc.
Helicon is focused on development of drugs to treat long-term memory
disorders and other central nervous system dysfunctions. But while studies of genetic
contributions to complex nervous system diseases are beginning to bear fruit, researchers
are a long way from understanding and effectively treating these maladies.